- Reuters•4 hours ago
Lung cancer is by far the biggest oncology market and a handful of companies have been jockeying for position in the battle to become dominant in initial, or first-line, treatment, and to provide much-needed combination therapies. Merck shares rose 3.8 percent to $62.60, while Bristol fell to $50.04. Bristol-Myers had suggested it would seek a path to swift approval of an Opdivo/Yervoy combination in first-line non-small cell lung cancer (NSCLC) only to reverse course after reviewing available data.
- Accesswire•8 hours ago
Upcoming AWS Coverage on AstraZeneca LONDON, UK / ACCESSWIRE / January 20, 2017 / Active Wall St. blog coverage looks at the headline from AbbVie Inc. (NYSE: ABBV ) as the Company announced on January ...
- Financial Times•yesterday
GlaxoSmithKline has poached its new global head of pharmaceuticals from rival AstraZeneca, marking a change of guard at Britain's biggest drugmaker as it prepares for the arrival of its new chief executive. ...
AZN : Summary for Astrazeneca PLC Common Stock - Yahoo Finance
AstraZeneca PLC (AZN)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Day's Range||26.86 - 27.41|
|52 Week Range||25.55 - 35.04|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||30.94|
|Dividend & Yield||0.90 (3.16%)|
|1y Target Est||N/A|